Physician profile
David Signarovitz
NPI 1922362235
$9,815.65
in general payments reported to CMS, 2019-2025
32 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,100 · 2020: $216 · 2021: $626 · 2022: $929 · 2023: $935 · 2024: $833 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,944.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,597.63 | 2019 | |
| Edwards Lifesciences Corporation | $930.48 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $625.82 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $619.82 | 2020-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $585.78 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Pressurewire |
| Boston Scientific Corporation | $504.42 | 2019-2025 | Avvigo Guidance System, Watchman Access System |
| Janssen Pharmaceuticals, INC | $493.84 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $480.09 | 2021-2025 | |
| Amgen INC. | $457.50 | 2021-2025 | Repatha, Repatha |
| Abiomed | $382.60 | 2020-2023 | Impella |
| Bard Peripheral Vascular, INC. | $150.00 | 2019 | |
| Kestra Medical Technology Services, INC. | $117.49 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.27 | 2023-2025 | Jardiance |
| Pfizer INC. | $113.05 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $82.01 | 2023-2025 | Opsumit, Uptravi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $76.19 | 2020-2025 | Wainua, Farxiga |
| Inspire Medical Systems, INC. | $68.18 | 2023-2025 | Inspire |
| Novo Nordisk INC | $66.18 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Bridgebio Pharma, INC. | $53.06 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $48.50 | 2022-2023 | Optimizer |
| Atricure, INC. | $37.22 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Philips North America LLC | $26.21 | 2022 | |
| Alnylam Pharmaceuticals INC. | $26.06 | 2025 | Onpattro |
| Teleflex LLC | $24.59 | 2025 | Vascband |
| Esperion Therapeutics, INC. | $21.72 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $20.33 | 2025 | |
| Lantheus Medical Imaging, INC. | $18.97 | 2025 | |
| La Jolla Pharmaceutical Company | $18.76 | 2025 | Giapreza |
| Daiichi Sankyo INC. | $15.73 | 2022 | |
| Terumo Medical Corporation | $14.08 | 2023 | Glidewire, Glidesheath Slender |
| Kiniksa Pharmaceuticals, LTD. | $12.88 | 2023 | Arcalyst |
| Biotronik INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Signarovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.